Table 5 Short form 36 results
From: An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer
Scale | Screening ( n =18) | 3 months ( n =11) | 6 months ( n =6) |
|---|---|---|---|
Physical functioning (PF) | 65.2 | 64.7 | 62.9 |
Social functioning (SF) | 77.2 | 79.7 | 75.1 |
Role limitation physical (RP) | 58.3 | 58.0 | 56.1 |
Role limitation emotional (RE) | 79.0 | 82.3 | 80.8 |
Bodily pain (BP) | 64.7 | 60.9 | 61.5 |
Mental health (MH) | 71.2 | 73.4 | 68.2 |
Vitality (VT) | 54.4 | 53.4 | 51.2 |
General health perception (GH) | 56.7 | 57.4 | 54.1 |
